Picture the regulatory affairs team at RiboX Therapeutics the morning the FDA’s IND clearance letter for RXIM002 arrived. The drug is not a conventional CAR-T. There is no apheresis. No ex vivo manufacturing. No six-week wait while a patient’s T-cells are harvested, engineered, and shipped back. Instead, RXIM002 delivers circular RNA via targeted lipid nanoparticles directly into the body, instructing the immune system to generate its own CAR-T cells on-site, in real time, against the B-cell antigens driving autoimmune cytopenias. The FDA cleared that concept as a Phase 1-worthy IND. That clearance is not a routine check-in-the-box — it is a structural signal about where the agency believes next-generation cell therapy science is heading.

RXIM002 carries a second layer of significance that deserves equal attention. This is not RiboX’s first IND clearance for a circular RNA platform. The company’s earlier candidate, RXRG001, already received FDA IND clearance for radiation-induced xerostomia, making it the first circular RNA therapy to enter the human trial pipeline. RXIM002 now extends that platform into autoimmune disease, a therapeutic area with a documented unmet need — the global Immune Thrombocytopenia (ITP) market alone was valued at approximately USD 2.5 billion in 2024, with growth projections driven by the inadequacy of existing immunosuppressive regimens. Two cleared INDs across two disease areas means the FDA has now reviewed and accepted the circular RNA construct more than once. The question clinical teams should be asking is what the agency actually required to get there.

The answer to that question is buried in the operational choices that rarely make it into press releases — and it has immediate consequences for anyone designing a first-in-class trial in 2026.

The In Vivo Difference Changes Everything About Your Protocol

Open the FDA’s January 2024 finalized guidance, “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products,” and read section by section with RXIM002 in mind. The guidance was written against a backdrop of ex vivo manufacturing — leukapheresis, viral vector transduction, cryopreservation, release testing, chain of custody. Nearly every manufacturing control in that document assumes the CAR-T cell was made outside the patient’s body. RXIM002 makes that assumption obsolete. The CAR-T cell is made inside the patient, by the patient’s own cells, after the LNP-delivered circular RNA instructs them to do so. That inverts the entire manufacturing paradigm and, with it, many of the protocol conventions that sponsors have treated as defaults.

Consider what this means for patient stratification. The FDA’s CAR-T guidance acknowledges that biomarker selection for patient eligibility must account for the biology driving T-cell function — prior lymphodepleting chemotherapy regimens, baseline immune status, and target antigen expression all influence whether an ex vivo product will engraft and expand. For an in vivo CAR-T delivered by LNP, the variables shift. Tropism of the LNP, endosomal escape efficiency, and the baseline competence of the recipient’s T-cell compartment become the upstream determinants of whether the circular RNA is translated at all. A patient who would have been eligible for an ex vivo product on clinical grounds might be a poor candidate for an in vivo product on pharmacological grounds — and that distinction needs to be baked into the Phase 1 eligibility criteria before the first patient is screened.

The early human data from in vivo CAR-T work in adjacent oncology settings suggests the biology can perform. A first-in-human study of in vivo CAR-T therapy in multiple myeloma reported that 100% of patients achieved MRD-negative responses by the first month, with responses deepening over time. That is a provocative early signal. But autoimmune cytopenias are not multiple myeloma, and the immune environment in ITP — where the pathology is an overactive rather than a deficient immune response — creates a different risk calculus for a therapy designed to expand T-cell populations in vivo.

What the FDA’s Manufacturing Guidance Cannot Yet Cover

Here is the counterintuitive reality of the RXIM002 clearance: the FDA’s existing manufacturing comparability framework was built for a world where the drug product leaves your facility. For circular RNA delivered by LNP, the “drug product” is the LNP-RNA construct. The biological activity — the CAR-T cell generation — happens inside the patient. The agency’s 2023 draft guidance on “Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products” addresses how sponsors should demonstrate that manufacturing changes do not alter the product. That guidance assumes there is a discrete biological product whose comparability can be assessed by release assays and functional potency tests. When the functional product is generated in vivo, release testing of the LNP construct is a necessary but insufficient proxy for biological comparability.

This gap has direct protocol implications. Sponsors designing a Phase 1 trial for an in vivo CAR-T construct need a pharmacodynamic biomarker strategy that can serve as a surrogate for the in vivo biological activity they cannot measure at release. For RXIM002 in autoimmune cytopenias, that almost certainly means serial monitoring of CAR-T cell expansion in peripheral blood, B-cell depletion kinetics, and autoantibody titers — all as exploratory endpoints in Phase 1, long before they become the primary endpoints of a registrational trial. The protocol cannot simply import the endpoint framework from an ex vivo CAR-T trial and expect it to fit.

Long-term safety monitoring adds another layer of complexity. The FDA’s draft guidance on “Postapproval Methods to Capture Safety and Efficacy Data for Cell and Gene Therapy Products” recommends long-term follow-up observational studies lasting up to 15 years for some cell and gene therapy products, with real-world data collection built into the post-market commitment structure. For circular RNA, which is not integrating into the genome, the theoretical genotoxicity risk profile differs from viral vector-based gene therapy. But the FDA has not yet issued specific guidance on whether that distinction reduces the long-term follow-up burden — meaning RXIM002’s Phase 1 sponsor should expect the agency to apply conservative assumptions until evidence supports otherwise.

What Sponsors Need to Do Before Their Pre-IND Meeting

The operational lesson from the RXIM002 clearance is that the FDA will engage with genuinely novel platform biology — but sponsors must come to the pre-IND meeting having already resolved the definitional questions that the agency’s existing guidance leaves open. For an in vivo RNA-based cell therapy, that means arriving with explicit positions on three things: how you define the “product” for release testing purposes, what pharmacodynamic biomarkers you will use as proxies for in vivo biological activity, and how your long-term follow-up plan addresses the specific safety signals relevant to your mechanism (cytokine release kinetics, on-target off-tumor B-cell depletion, and reversion of autoimmune pathology without creating immunodeficiency).

The pre-IND meeting request for a program like this should explicitly invoke the FDA’s CAR-T guidance while flagging where the in vivo mechanism creates gaps in its applicability. That framing does two things: it signals that the sponsor understands the regulatory architecture, and it puts the agency on notice that the sponsor is asking for platform-specific guidance rather than trying to fit a circular RNA product into a CAR-T-shaped box. RiboX has now done this twice, across two disease areas, and received clearance both times. The precedent exists. The blueprint, however, still needs to be drawn by each sponsor for their own platform.

The global ITP market’s USD 2.5 billion valuation and the documented inadequacy of chronic immunosuppression in autoimmune cytopenias mean the commercial logic for pursuing this space is straightforward. The regulatory logic is more demanding — but the RXIM002 clearance confirms the FDA is willing to walk that path with sponsors who have done the mechanistic and manufacturing homework before asking the agency to sign off.

The regulatory affairs team that opened that IND clearance letter knew they were not just getting a green light for a Phase 1 trial. They were receiving confirmation that the FDA had accepted, for the second time, that circular RNA belongs in the clinic. The next question — the one that will define whether this platform reaches patients — is whether the Phase 1 protocol they now execute is sophisticated enough to generate the data the agency will need to answer its own outstanding questions about in vivo CAR-T safety, durability, and dose-response. That protocol is being written right now, and every choice in it carries forward the weight of a regulatory milestone that the broader cell therapy field is only beginning to process.

References

  1. PR Newswire — “RiboX Therapeutics Announces FDA IND Clearance for RXIM002, the first Circular RNA-Based in vivo CAR Therapy for Autoimmune Cytopenias”
  2. CGTLive — “RiboX Circular RNA Therapy RXRG001 Cleared for Phase Trial in Radiation-Induced Xerostomia and Hyposalivation”
  3. ASCO Post — “Early Findings from First Human Study of In Vivo CAR-T in Myeloma”
  4. Strategic Market Research — “Immune Thrombocytopenia Market Report”
  5. FDA — “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products” (Finalized January 2024)
  6. DIA Global Forum — “New FDA Guidance Addresses Challenges with Cell and Gene Manufacturing Comparability and Complexity” (November 2023)
  7. BioPharm International — “New FDA Guidance Utilizes Real-World Data and AI for Postmarket CGT Surveillance”
Website |  + posts

Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.